Clinical effectiveness and adverse events associated with tolvaptan in patients above 90 years of age with acute decompensated heart failure
Sign Up to like & getrecommendations! Published in 2021 at "Heart and Vessels"
DOI: 10.1007/s00380-020-01753-3
Abstract: With the aging society, the number of very-elderly (VE) patients with acute decompensated heart failure (ADHF) is increasing. Although tolvaptan is recommended for patients with ADHF in whom conventional diuretic therapy is ineffective, few reports… read more here.
Keywords: age; years age; group; nve group ... See more keywords